Article
Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Journal of cellular physiology - 1 Feb 2007
Emdad Luni, Lebedeva Irina V, Su Zao-Zhong, Gupta Pankaj, Sarkar Devanand, Settleman Jeffrey, Fisher Paul B
Abstract excerpt
Activation of the epidermal growth factor receptor (EGFR) contributes to the pathogenesis of non-small-cell lung carcinomas (NSCLC) and gefitinib, a selective reversible EGFR inhibitor, is effective in treating patients with NSCLC. However, clinical resistance to gefitinib is a frequent occurrence highlighting the need for improved therapeutic strategies. Melanoma differentiation associated gene-7...
Topics
- Adenoviridae
- Adenoviridae Infections
- Antineoplastic Agents
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Enzyme Inhibitors
- Epidermal Growth Factor
- Gefitinib
- Gene Expression Regulation, Neoplastic
- Genetic Therapy